Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
Authors (first, second and last of 6)
Discover Oncology, formerly Hormones and Cancer, is part of the Discover journal series committed to providing a streamlined submission process, rapid review and publication, and a high level of author service at every stage. It is an open access, community-focussed journal publishing content that interfaces at all levels of cancer research.
- Publishing research from across all fields relevant to oncology
- Covers basic and translational science, through to preclinical, clinical, and epidemiology
- A Discover journal focused on speed of submission and review, service, and integrity
Journal information
- Editor-in-Chief
-
- Eleonora Candi
- Publishing model
- Open Access. How to publish with us
Journal metrics
- 4.667 (2021)
- Impact factor
- 3.607 (2021)
- Five year impact factor
- 3 days
- Submission to first decision (Median)
- 144,984 (2021)
- Downloads
Latest issue
Latest articles
-
-
-
Nonconvulsive status epilepticus characteristics in glioma patients: a retrospective study
Authors (first, second and last of 5)
-
Cardiac dose in the treatment of synchronous bilateral breast cancer patients between three different radiotherapy techniques (VMAT, IMRT, and 3D CRT)
Authors (first, second and last of 6)
-
Journal updates
-
Discover Oncology partners with IABCR
Discover Oncology is supporting the IABCR 2023: 32nd International Association for Breast Cancer Research Conference from 01 – 04 May 2023 in the Riviera Maya, Mexico. and we are inviting you to join the conference, in May 2023, Mexico.
Several $1000 grants are available for early career researchers. Please visit the conference website for details. -
Discover Oncology has an impact factor of 4.67
Hormones and Cancer changed its title to Discover Oncology in 2021, and under the new title the journal continues to be included in the major indexing services it was previously (e.g. PubMed, Scopus, SCIE).
For the journal's Impact Factor as calculated by Clarivate, the Web of Science Master List entry for Discover Oncology displays the Impact Factor as 4.67.
-
Hormones and Cancer is now Discover Oncology
As of January 2021 Hormones and Cancer (eISSN: 1868-8500) has been relaunched as Discover Oncology (eISSN: 2730-6011), a fully open access journal covering all aspects of cancer research. As a fully open access journal, all content is published under a CC BY open access license, and freely available to readers worldwide, enabling the widest possible dissemination and reuse. All non-OA content published prior to the title change is now free-to-read. Find out more
-
Meet the Editor-in-Chief for Discover Oncology
Learn more about our Editor-in-Chief
About this journal
- Electronic ISSN
- 2730-6011
- Abstracted and indexed in
-
- BIOSIS
- Baidu
- Biological Abstracts
- CLOCKSS
- CNKI
- CNPIEC
- Chemical Abstracts Service (CAS)
- DOAJ
- Dimensions
- EBSCO Discovery Service
- EMBASE
- Google Scholar
- INIS Atomindex
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- Naver
- OCLC WorldCat Discovery Service
- Portico
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- PubMedCentral
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index Expanded (SCIE)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Wanfang
- Copyright information